Despite targeting the same orphan indication for kidney transplants, Hansa Biopharma had to conduct completely separate clinical trials for Europe and the US. This highlights how differing regulatory demands from the FDA (requiring a control arm) and EMA can significantly increase costs and complexity for global biotech companies.
The European biotech's US listing strategy is threefold: to be present in its primary commercial market, to offer stock options to attract and retain specialized American talent, and to access a deeper pool of specialist investors that is unavailable in Europe's fragmented public markets for growth companies.
The same technology used for kidney transplants is being repurposed to solve a key problem in gene therapy. By temporarily clearing pre-existing antibodies against AAV delivery vectors, the platform enables patients who would otherwise be disqualified to receive potentially life-saving gene therapies, creating a new high-value market.
The company's IgG-lowering drug is not a lifelong immunosuppressant but a single-use therapy. Its purpose is to enable a life-changing event—a kidney transplant—that would otherwise be impossible for highly sensitized patients. This "acute enabler" model simplifies long-term care, as patients revert to standard post-transplant protocols afterward.